Nilotinib is a second-generation tyrosine kinase inhibitor used to treat patients with BCR-ABL positive chronic myelogenous leukemia (CML) [23,78]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.